Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy

OncoImmunology

Volumn 2, Issue 8, 2013, Pages

  Swarbrick, Alexander ^a,b   Junankar, Simon R ^a   Batten, Marcel ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

3 methylcholanthrene; Interferon ; Interleukin 27; Polyomavirus middle T antigen (PyMT) induced mammary carcinoma; Tregs

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR ALPHA; INTERLEUKIN RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; KIDNEY CARCINOMA; METASTATIC MELANOMA; NEOPLASM; NONHUMAN; REGULATORY T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; UNSPECIFIED SIDE EFFECT;

EID: 84885766328     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25409     Document Type: Article

References (10)

1. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16; PMID:10561265
2. Reeves DJ, Liu CY. Treatment of metastatic renal cell carcinoma. Cancer Chemother Pharmacol 2009; 64:11-25; PMID:19343348; http://dx.doi. org/10.1007/s00280-009-0983-z
3. Hunter CA, Kastelein R. Interleukin-27: balancing protective and pathological immunity. Immunity 2012; 37:960-9; PMID:23244718; http://dx.doi. org/10.1016/j.immuni.2012.11.003
4. Xu M, Mizoguchi I, Morishima N, Chiba Y, Mizuguchi J, Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010; 2010:2010; PMID:20885915; http://dx.doi. org/10.1155/2010/832454
5. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29:235-71; PMID:21219185; http://dx.doi.org/10.1146/annurevimmunol- 031210-101324
6. Teng MWL, Ngiow SF, von Scheidt B, McLaughlin N, Sparwasser T, Smyth MJ. Conditional regulatory T-cell depletion releases adaptive immunity preventing carcinogenesis and suppressing established tumor growth. Cancer Res 2010; 70:7800-9; PMID:20924111; http://dx.doi.org/10.1158/0008-5472.CAN-10-1681
7. Emtage PCR, Wan Y, Hitt M, Graham FL, Muller WJ, Zlotnik A, et al. Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Hum Gene Ther 1999; 10:697-709; PMID:10210138; http://dx.doi. org/10.1089/10430349950018463
8. Pützer BM, Bramson JL, Addison CL, Hitt M, Siegel PM, Muller WJ, et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer. Hum Gene Ther 1998; 9:707- 18; PMID:9551618; http://dx.doi.org/10.1089/ hum.1998.9.5-707
9. Natividad KD, Junankar SR, Mohd Redzwan N, Nair R, Wirasinha RC, King C, et al. Interleukin-27 signaling promotes immunity against endogenously arising murine tumors. PLoS One 2013; 8:e57469; PMID:23554861; http://dx.doi.org/10.1371/journal. pone.0057469
10. Salcedo R, Hixon JA, Stauffer JK, Jalah R, Brooks AD, Khan T, et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009; 182:4328-38; PMID:19299733; http://dx.doi.org/10.4049/jimmunol. 0800471